Overview
FOSUN PHARMA (2196)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments:...
- Open
- 16.510
- High
- 16.810
- Low
- 16.100
- Prev. Close
- 16.570
- Volume
- 3.40M
- Turnover
- 55.25M
- Avg Price
- 16.265
- Bid/Ask Ratio
- -83.33%
- Amplitude
- 4.28%
- 52wk High
- 23.050
- Volume Ratio
- 1.12
- Turnover Ratio
- 0.65%
- 52wk Low
- 14.450
- HK Mkt Cap
- 8.44B
- Market CapHKD
- 42.74B
- P/ETTM
- 10.44
- P/EDynamic
- 10.32
- P/EStatic
- --
- EPSTTM
- 1.55
- EPSDynamic
- 1.57
- EPSStatic
- --
- BVPS
- 22.20
- P/B
- 0.73
- HK Shares
- 521.52M
- Dividend YieldTTM
- 2.80%
- DividendTTM
- 0.453
- Shares
- 2.64B
- Min lot size
- 500
- Currency
- HKD
FOSUN PHARMA Analyst Rating
View moreForecast & Rating
Nov 4, 2026- Strong buy20.00%
- Buy40.00%
- Hold40.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 2
- Hold
- 2
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
Fosun Pharma declined approximately 2.3% today, retreating from morning high of HK$16.74 to close at HK$16.19. Frequent share buybacks underscore management's concern over persistent share underperformance. Q3 results delivered solid earnings growth: EPS surged 24.38% year-over-year to HK$0.4214, net profit climbed 23.29% to HK$1.107B, and operating profit jumped 42.2%. Valuations remain deeply discounted, with PE of just 10.44 and PB of 0.73, yet such extreme marks may reflect market skepticism on growth trajectory rather than true bargains. Price action reveals weakness: down 18.85% year-to-date and 31.11% below the 52-week high of HK$23.50. Subsidiary Fosun Kairos advanced FKC516 into Phase II trials for B-cell lymphoma, providing medium-term catalysts. However, structural pressures in China's pharmaceutical sector and persistent share weakness suggest near-term recovery remains uncertain.
- Nov, 13
Fosun Pharma shares closed flat at HKD 16.57 after morning gains, reflecting a pullback in afternoon trading. The stock found support from strong Q3 results, with EPS jumping 24.38% year-over-year to HKD 0.4214, net profit surging 23.29% to HKD 1.107 billion, and operating profit up 42.2%, showcasing significant margin improvement. A new catalyst emerged as subsidiary Fosun Kairos initiated Phase II trials for FKC516, an innovative B-cell lymphoma treatment, while ongoing share buybacks signal management confidence. However, year-to-date weakness of -16.94% from a starting price of HKD 19.95, combined with a -29.49% gap from the 52-week high of HKD 23.5, illustrates the stock's extended pullback. The 60-day moving average of HKD 17.082 also sits above current levels, though attractive valuation metrics (PE 10.69, PB 0.75) and a 2.73% dividend yield provide a cushion.
- Nov, 12
Shares closed at 16.57 HKD, down roughly 1% from previous close of 16.73, after reaching intraday high of 16.71 in the morning session before succumbing to afternoon selling pressure. Q3 earnings showed solid fundamentals with EPS of 0.4214 HKD rising 24.38% year-over-year, operating profit surging 42.2% YoY, and operating revenue of HK$11.73 billion up 8.58% YoY, with net margin expanding to 9.44%. However, the stock has declined 16.94% year-to-date and sits 29.49% below the 52-week high of 23.5 HKD, trading at depressed valuations of PE 10.69 and PB 0.75. Trading volume remained light at 0.40% turnover. Management's repeated share buyback announcements signal confidence in the valuation, yet the broader pharmaceutical sector headwinds appear to be weighing on sentiment, with investor concerns about industry growth prospects limiting the stock's ability to capitalize on improving fundamentals.
- Nov, 11
Fosun Pharma declined roughly 2% to close at HKD 16.73 today, primarily reflecting profit-taking after the previous week's 3.67% surge triggered by strong Q3 financial results. The company posted robust earnings with net profit of HKD 1.107 billion, up 23.29% year-over-year, and EPS of HKD 0.4214, representing a 24.38% year-over-year increase, while operating profit jumped 42.2% on a year-over-year basis. After climbing to an intraday high of HKD 16.98 at 9:40 AM, the stock retreated through the afternoon session, exemplifying the classic sell-the-news dynamic following earnings-driven rallies. Recent filings reveal multiple share buyback transactions, reflecting management's continued support for the share price. From a valuation perspective, the stock trades at an attractive PE of 10.79 and PB of just 0.75—trading well below book value—while YTD performance shows a 16.14% decline and remains approximately 30% below its 52-week peak, offering a meaningful valuation cushion.
- Nov, 10
Shanghai Fosun Pharmaceutical rose 1.31% to HK$17.08 today, driven by strong Q3 results released recently. Operating profit surged 42.2% year-over-year, rebounding sharply from Q2's -26.73% decline; net profit grew 23.29% to HK$1.107 billion, with EPS of HK$0.4214, up 24.38% YoY. Beyond the earnings recovery, the company continues share buybacks and portfolio optimization, including the sale of its Gland stake to fuel neurofibromatosis drug development. Regarding valuation, Fosun trades at compressed multiples with PE of 11.02 and PB of 0.77, offering a dividend yield of 2.65%; year-to-date the stock is down 14.39%, still 30% below the 52-week high of HK$24.42.
News
PUBT · Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in China
PUBT · Shanghai Fosun Pharmaceutical Files Next-Day HKEX Return Announcing Share Buyback
PUBT · Fosun Pharma Subsidiary Fosun Kairos Starts Phase II Trial of FKC516 for B-Cell Lymphoma
prnewswire · Accro Bioscience Announces First Patient Enrolled in Phase II/III Clinical Trial of Highly Selective TYK2/JAK1 Inhibitor AC-201 for Non-Segmental Vitiligo
Weekly Review · Weekly Recap | FOSUN PHARMA +3.67%, consensus target above spot
PUBT · Shanghai Fosun Pharma Files HKEX Next-Day Disclosure on Share Buyback
